Union Minister and BJP national president J P Nadda with senior party leader V Muraleedharan and others at an event in Palakkad on Sunday 
Kerala

Kerala govt delaying action on Hema committee report as their own people involved: JP Nadda

“Why there is a delay in (release of) Justice Hema Committee report? What is stopping the Kerala government?, the Union Minister and BJP national president asked.

Shyam P V

PALAKKAD: Union Minister and BJP national president J P Nadda on Sunday alleged that the Kerala government delayed publishing the Justice Hema Committee report and initiating action based on the report because “their own people are involved” in the sexual harassment controversies that have rocked the Malayalam film industry and state politics.

Nadda was addressing an interactive programme titled Moments with Naddaji, organised by the BJP state leadership and attended by eminent personalities from Palakkad. Nadda is in Palakkad to attend RSS’ three-day annual Akhil Bharatiya Samanvay Baithak, organised for the first time in Kerala, which culminates on Monday.

“Why there is delay in (release of) Justice Hema Committee report? What is stopping the Kerala government? What is haunting you? Because you are part and parcel of that. It is something you want to hide because your people are involved,” Nadda said at the interactive session.

He accused Kerala of having become a land of corruption, citing the Karuvannur cooperative bank scam as an example. “Even the chief minister’s office is not immune from corruption and the Kerala government is playing hide-and-seek in the Justice Hema Committee report,” alleged Nadda.

Why the additional declaration linked to Form 6 is facing a legal challenge

SP-Congress alliance faces fresh strain as Akhilesh skips INDIA bloc meet over UP seat-sharing talks

Rahul Gandhi tells CWC to continue 'resistance' against 'match-fixing' of polls through EVM, voters list

Assam Rifles jawan killed in militant attack in Arunachal; security forces intensify ops to arrest killers

SC slams medicine pricing, calls cancer drug’s 10-fold MRP markup ‘carnage’